Formiminotransferase Cyclodeaminase Suppresses Hepatocellular Carcinoma by Modulating Cell Apoptosis, DNA Damage, and Phosphatidylinositol 3-Kinases (PI3K)/Akt Signaling Pathway

Jiajia Chen* 
Zemian Chen*
Zhentian Huang
Hongrong Yu
Yanbing Li
Wenhua Huang

Background: Formiminotransferase cyclodeaminase (FTCD) is a candidate tumor suppressor gene in hepatocellular carcinoma (HCC). However, the mechanism for reduced expression of FTCD and its functional role in HCC remains unclear. In this study, we explored the biological functions of FTCD in HCC.

Material/Methods: The expression and clinical correlation of FTCD in HCC tissue were analyzed using TCGA (The Cancer Genome Atlas) and a cohort of 60 HCC patients. The MEXPRESS platform was accessed to identify the methylation level in the promoter region of FTCD. CCK-8 assay and flow cytometry analysis were used to explore the proliferation, cell apoptosis proportion, and DNA damage in HCC cells with FTCD overexpression. Western blot analysis was performed to identify the downstream target of FTCD.

Results: FTCD is significantly downregulated in HCC tissues and cell lines. Low FTCD expression is correlated with a poor prognosis (P<0.001) and an aggressive tumor phenotype, including AFP levels (P=0.009), tumor size (P=0.013), vascular invasion (P=0.001), BCLC stage (P=0.024), and pTNM stage (P<0.001). Bioinformatics analysis indicated promoter hypermethylation can result in decreased expression of FTCD. FTCD overexpression suppressed cell proliferation by promoting DNA damage and inducing cell apoptosis in HCC cells. FTCD overexpression resulted in increased level of PTEN protein, but a decrease in PI3K, total Akt, and phosphorylated Akt protein in HCC cells, suggesting involvement of the PI3K/Akt pathway.

Conclusions: FTCD acts as a tumor suppressor gene in HCC pathogenesis and progression and is a candidate prognostic marker and a possible therapeutic target for this disease.

MeSH Keywords: Apoptosis • Carcinoma, Hepatocellular • DNA Damage • Glutamate Formimidoyltransferase • Phosphatidylinositol 3-Kinases

Full-text PDF: https://www.medscimonit.com/abstract/index/idArt/916202
Background

Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related death worldwide [1]. Epidemiological data indicate that there are approximately 750,000 new cases of liver cancer diagnosed globally per year [2]. The vast majority of HCC occurs from chronic liver disease due to type B or C hepatitis virus infection, alcohol abuse, and nonalcoholic steatohepatitis [3]. Thus, the poor parenchymal reserve of patients increases the challenge of treating patients with HCC. Although nonsurgical treatment platforms and standardization of liver transplant have improved, the 5-year survival rate is only about 26% in the United States [4]. Recent studies suggested that the loss of certain tumor suppressors and the deregulation of numerous signaling modules such as cell differentiation (WNT, Hedgehog, Notch), cell growth factor signaling (IGF, EGF, PDGF), and angiogenesis (VEGF) may play critical roles in HCC development and progression [5]. Therefore, identifying new molecules involved in the development and progression of HCC might accelerate the understanding of the mechanism involved in the development and progression of HCC, as well as providing new drug targets for HCC treatment.

Formiminotransferase cyclodeaminase (FTCD) is expressed in every mammalian cell type, but, interestingly, is most highly accumulated in the liver [6]. FTCD contains 2 active sites (FT and CD) at different positions on the protein structure, and catalyzes histidine degradation during the folate metabolism process [7]. Furthermore, in addition to participating in the metabolic process, FTCD is also associated with Golgi complex [8]. Recently, using a CRISPR-Cas9-based screen, FTCD was found to be associated with chemotherapeutic drug sensitivity. The deletion of the genes in the histidine degradation pathway markedly decreased sensitivity to methotrexate, meaning that dietary supplementation of histidine can increase flu x through the histidine degradation pathway and could enhance sensitivity to methotrexate [9]. In HCC, FTCD is significantly down-regulated in tumor tissues and can serve as a useful diagnostic biomarker to distinguish early HCC from benign tumors [10]. However, the detailed molecular function of FTCD in tumors remains unclear and its downstream pathways still must be comprehensively determined.

In the present study, we determined via the Cancer Genome Atlas (TCGA) data set and our case cohort that FTCD expression was decreased in HCC and negatively correlated with disease progression. Notably, we found the abnormal expression of FTCD was due to the high methylation level in the promoter region. In vitro experiments showed a tumor-suppressive role of FTCD. The overexpression of FTCD inhibited the proliferation of HCC cells and promoted cell apoptosis and DNA damage. Furthermore, activation of the PI3K/Akt pathway was decreased after FTCD overexpression. These findings indicate that FTCD suppresses tumor progression in HCC and could be a potential new target for therapeutic interventions against HCC.

Material and Methods

Human tissue samples

This study was reviewed and approved by the Medical Ethics Committee of Nanfang Hospital of Southern Medical University, and the tissue samples were used with the informed written consent of the patients, according to the Declaration of Helsinki. The study comprised 60 pairs of randomly selected paraffin-embedded HCC tissue samples and paired non-tumor samples from patients who underwent resection of liver cancer without preoperative chemotherapy or radiotherapy. All samples were histologically confirmed by 2 independent pathologists.

Cell lines

HL-7702, Huh7, BEL-7402, SNU449, and SK-Hep1 cell lines were purchased from the Cell Bank of Type Culture Collection (Chinese Academy of Sciences, Shanghai, China). HL-7702, BEL-7402, Huh7, and SK-Hep1 cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM; Gibco), and SNU449 cells were cultured in RPM1640 medium (Gibco). Cells were incubated with 10% fetal bovine serum (FBS; Gibco; Carlsbad, CA, USA) at 37°C in a humidified atmosphere containing 5% CO₂.

Immunohistochemical staining

Paraffin-embedded tissue samples were sliced into 4-µm sections, which were then routinely processed for immunohistochemistry. After incubation with an antibody against FTCD (1: 100; Proteintech, Rosemont, IL, USA), the sections were stained with diaminobenzidine in the Envision System (Dako, Carpinteria, CA, USA). FTCD protein expression in 60 paired tissue samples was classified into a positive group and a negative group based on staining intensity and extent, as previously described [11].

Gene expression datasets

A cohort from the TCGA Liver Hepatocellular Carcinoma (TCGA-LHC) dataset (https://portal.gdc.cancer.gov) was used to analyze the expression pattern of FTCD and its correlation with clinical features. The database includes 442 HCC patients with FTCD expression based on RNA-Seq. It also contains 51 pairs of HCC and normal liver tissues. The fold change of FTCD expression in the HCC samples compared with that in the paired normal samples were calculated as previously described [12]. In addition, FTCD DNA methylation profile was analyzed using the MEXPRESS (http://mexpress.be) platform.
**De-methylation treatment**

Cells were treated with growth medium containing 10 μM of 5-Aza (Sigma, St Louis, MO, USA) for 72 h. The growth medium and drug were replaced daily. Control cells were treated in parallel with DMSO agent.

**Cell transfection**

Cells were seeded into 6-well plates at a density of 3×10^5 cells per well and transfected with the pc-DNA3.1(+)−FTCD plasmid (GenePharma, Shanghai, People’s Republic of China) or vector control when they reached 70–80% confluence using Lipofectamine 3000 Reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer’s protocol. Cells were cultured for 48 h before further experiments.

**Real-time RT-PCR assay**

Total RNA was extracted with RNAiso (TaKaRa, Tokyo, Japan) and then reverse transcribed to cDNA with PrimeScript RT Master Mix (TaKaRa) according to the manufacturer’s instructions. The relative FTCD expression, normalized to expression of the endogenous control GAPDH, was determined by qPCR assay using the SYBR Premix Ex Taq II Kit (TaKaRa). Fold changes were calculated using the 2^ΔΔCT method. The primers were: FTCD forward: 5'-GCG TGT TTG GCG CAT ATT-3' and reverse: 5'-GAT GGT GGA TCT GGT CCT TAA A-3'; GAPDH forward: 5'-AAG AAG AUG CGG CUG ACU GUC-3' and reverse: 5'-CAG UCA GCC GCA UCU UCU UUU-3'.

**Western blot analysis**

Total protein was extracted using RAPI (Beyotime, Shanghai, People’s Republic of China) buffer mixed with the protease inhibitor phenylmethanesulfonyl fluoride (Beyotime). Equivalent protein was separated by 10% sodium-dodecyl-sulfate-polyacrylamide-gel electrophoresis (Fdbio Science, Hangzhou, China) and electro-transferred to polyvinylidene difluoride membranes (Millipore, Bedford, MA, USA). The membranes were then blocked with 5% bovine serum albumin and incubated with primary antibodies overnight at 4°C, followed by incubation with horseradish-peroxidase-labeled secondary antibody (1: 10 000; Proteintech). Immunodetection was performed using an ECL substrate kit (Millipore). The primary antibodies were: anti-FTCD rabbit polyclonal antibody (1: 5000; Proteintech), anti-Akt rabbit polyclonal antibody (1: 1000; Cell Signaling Technology, Boston, MA, USA), anti-Akt rabbit polyclonal antibody (1: 1000; Cell Signaling Technology), anti-phospho-AktSer473 (pAkt) rabbit polyclonal antibody (1: 1000; Cell Signaling Technology), anti-PI3K rabbit polyclonal antibody (1: 2000; Cell Signaling Technology), and anti-GAPDH rabbit polyclonal antibody (1: 10 000; Proteintech).

**CCK-8 assay**

Cells were seeded into 96-well plates at a density of 3×10^4 cells per well. CCK-8 solution (Dojindo Laboratories, Osaka, Japan) (10 μl/well) was added at 0, 24, 48, 72, and 96 h after adherence by using CCK-8 (Solarbio, Beijing, People’s Republic of China) according to the manufacturer’s protocol. Absorbance was recorded at 450 nm with a microplate reader.

**Flow cytometric analysis**

Cells (1×10^5) were trypsinized and resuspended into single-cell suspensions. They were separately treated with BrdU In-Situ Detection Kit (BD Biosciences, San Jose, CA, USA), Cell Apoptosis Detection Kit (KeyGEN, Nanjing, China) and Alexa Fluor® 647 Mouse anti-H2AX reagent (BD Biosciences) according to manufacturer’s instructions. Stained cells were analyzed with a flow cytometer, and the data were analyzed and plotted using FlowJo software (Tree Star, Inc, Ashland, OR, USA).

**Statistical analysis**

Data from 3 independent experiments were presented as mean ±SEM. GraphPad Prism 7.0 (GraphPad Software, Inc, La Jolla, CA, USA) or IBM SPSS Statistics 20.0 (IBM, Armonk, IL, USA) was utilized to perform statistical analysis. All statistical analyses were performed using the Pearson chi-squared test, 2-tailed t test, or analysis of variance (ANOVA), as appropriate. P<0.05 (2-tailed) was considered statistically significant.

**Results**

Decreased expression of FTCD correlates with the progression of HCC

To identify the role of FTCD in HCC, we scanned the transcriptomic data from the TCGA-LIHC data set and found that the mRNA levels of FTCD in patients with HCC were significantly downregulated in the tumor samples relative to the levels in normal liver tissues. We found that 92.0% (46/50) of the paired normal samples had an average 2.88-fold increased expression of FTCD compared with tumor samples (Figure 1A, 1C). In addition, the distribution of FTCD mRNA levels was significantly decreased in the patients with advanced T stage (P<0.001, Figure 1D) or poor survival time (P<0.001, Figure 1E). We also found that FTCD was downregulated in HCC cells compared to normal liver cell line HL-7702 (Figure 1F, 1G).

To validate our bioinformatic analysis findings, we analyzed FTCD expression by IHC in a cohort containing 50 pairs of HCC/non-tumor tissues. Results showed that FTCD protein located in the cytoplasm of HCC tissues and its expression
levels was significantly lower in HCC tissues than in adjacent normal liver tissues \((P < 0.05, \text{Figure 1B})\).

To clarify the clinical significance of FTCD in HCC development, we assessed the correlation between FTCD expression and clinicopathological parameters of patients with HCC. As shown in Table 1, positive FTCD expression was strongly associated with low AFP levels \((P = 0.009)\), smaller tumor size \((P = 0.013)\), absence of vascular invasion \((P = 0.001)\), early BCLC stage \((P = 0.024)\), and early pTNM stage \((P < 0.001)\). Collectively, these findings strongly suggest that FTCD is downregulated in HCC, and its abnormal expression might contribute to disease progression.

**Figure 1.** Decreased expression of FTCD contributes to the progression of HCC. (A) FTCD mRNA relative expression in HCC and normal samples from the TCGA-HCC data set. Data presented as log2 (cancer/non-cancer). (B) FTCD mRNA expression in HCC and normal samples from the TCGA-HCC data set. (C) Representative images of immunohistochemical staining against HCC in 60 tumor/normal matched sample pairs. (D) Correlation analysis of FTCD mRNA expression and T stage based on the TCGA-HCC data set. (E) Kaplan-Meier survival analysis of patients with HCC based on the TCGA-HCC data set. (F) qRT-PCR analysis of FTCD mRNA expression in normal liver cells and 4 HCC cells. (G) Western blot analysis of FTCD protein expression in normal liver cells and 4 HCC cells. All experiments were performed in triplicate and results are expressed as means ±SD.

\(* * P < 0.01, ** P < 0.001.\)
Promoter methylation contributes to the decreased expression of FTCD in HCC

To uncover the mechanism involved in the decreased FTCD expression in HCC, we analyzed the methylation status of FTCD in 374 tumor tissues and 40 normal tissues via MEXPRESS, a web tool for visualization of the DNA methylation based on the TCGA data on a single-gene level. Figure 2A shows the whole methylation profile of FTCD. Significantly, 5 CpG sites had greater hypermethylation in the HCC samples than in the normal tissues (\(P<0.001\), Figure 2A). A notable negative correlation between DNA methylation and FTCD transcription was also observed (\(r=–0.394, P<0.001\), Figure 2B). To evaluate the methylation status of FTCD in vitro, BEL-7402 and SNU449 cells

### Table 1. Correlation between the FTCD protein expression and the clinicopathological parameters.

| Variable                          | Cases | FTCD protein expression | \(\chi^2\) value | \(P\) value |
|-----------------------------------|-------|-------------------------|-----------------|-------------|
|                                   |       | Positive | Negative |               |             |
| Sex                               |       | 49       | 29       | 20           | 0.080       | 0.778       |
| Male                              |       | 29       | 20       |               |             |
| Female                            |       | 6        | 5        |               |             |
| Age                               |       | 48       | 21       | 27           | 0.017       | 0.896       |
| <60 years                         |       |          |          |               |             |
| ≥60 years                         |       | 12       | 5        | 7            |             |
| Serum HBsAg                       |       | 11       | 14       |               | 3.135       | 0.077       |
| Positive                          |       |          |          |               |             |
| Negative                          |       | 49       | 17       | 32           |             |
| AFP                               |       | 6        | 10       | 4            |             |
| <400 μg/L                         |       | 22       | 14       | 8            |             |
| ≥400 μg/L                         |       | 38       | 11       | 27           |             |
| Tumor size                        |       |          |          |               |             |
| ≤5 cm                             |       | 26       | 16       | 10           | 6.193       | 0.013       |
| >5 cm                             |       | 34       | 10       | 24           |             |
| Tumor number                      |       |          |          |               |             |
| Solitary                          |       | 52       | 22       | 24           | 2.891       | 0.089       |
| Multiple                          |       | 9        | 2        | 7            |             |
| Histological grade                |       |          |          |               |             |
| Well                              |       | 16       | 10       | 6            | 4.470       | 0.093       |
| Moderate                          |       | 31       | 16       | 15           |             |
| Poor                              |       | 13       | 3        | 10           |             |
| Vascular invasion                 |       |          |          |               |             |
| Absent                            |       | 50       | 38       | 12           | 11.760      | 0.001       |
| Present                           |       | 10       | 2        | 8            |             |
| BCLC stage                        |       |          |          |               |             |
| 0-A                               |       | 41       | 26       | 15           | 7.493       | 0.024       |
| B                                 |       | 9        | 3        | 6            |             |
| C                                 |       | 10       | 2        | 8            |             |
| pTNM stage                        |       |          |          |               |             |
| I/II                              |       | 15       | 3        | 12           | 14.689      | 0.000       |
| III/IV                            |       | 45       | 34       | 11           |             |

HBsAg = hepatitis B surface antigen; AFP = α-fetoprotein; pTNM = pathological Tumor Node Metastasis; BCLC = Barcelona Clinic Liver Cancer.

Hepatitis B surface antigen; α-fetoprotein; pathological Tumor Node Metastasis; BCLC = Barcelona Clinic Liver Cancer.
were treated with 5-Aza, an inhibitor of DNA methyltransferase, and the results indicated that both the FTCD mRNA and protein levels were significantly increased in the 5-Aza-treated group compared with the levels in the control group (\(p<0.001\), Figure 2C, 2D). Therefore, the results indicated that the promoter region of FTCD was hypermethylated, which might, in part, lead to the decrease in FTCD expression in HCC.

Overexpression of FTCD inhibits HCC cell proliferation

To investigate the potential biological role of FTCD expression in the development and progression of HCC, we next performed cell function studies in HCC cells. After detecting FTCD expression in HCC cell lines (Figure 3A, 3B, 3E, 3F), we developed BEL-7402 and SNU499 cell lines with FTCD overexpression. By performing CCK-8 assay during a consecutive time segment, we discovered that FTCD overexpression reduced the proliferative capacity of HCC cells compared with that of parallel cell lines containing the empty vector (Figure 3C, 3G). BrdU assay with flow cytometry analysis was also performed to evaluate the proportion of proliferating cells and revealed that the proportion of BrdU-positive cells decreased in FTCD-overexpressing cells (Figure 3D, 3H).

Overexpression of FTCD induces cell apoptosis and promotes DNA damage in HCC

To discover the underlying molecular mechanism by which FTCD inhibits HCC cell proliferation, we analyzed differences in cell apoptosis rates after FTCD overexpression by flow cytometry analysis. The results showed that FTCD overexpression induced more apoptotic BEL-7402 and SNU499 cells compared to the control cells (Figure 4A, 4C).
Figure 3. Overexpression of FTCD inhibits cell proliferation in HCC. (A, E) qRT-PCR verified the overexpression of FTCD in BEL-7402 and SNU449 cells. (B, F) Western blot analysis verified the overexpression of FTCD in BEL-7402 and SNU449 cells. (C, G) Cell viability analysis of BEL-7402 and SNU449 cells with FTCD overexpression. (D, H) Flow cytometric analysis of BrdU-labeled BEL-7402 and SNU449 cells with FTCD overexpression. All experiments were performed in triplicate and results are expressed as means ±SD. ***P<0.001.
Figure 4. Overexpression of FTCD induces cell apoptosis and leads to DNA damage in HCC. (A, C) Flow cytometric analysis of cell apoptosis rates of BEL-7401 and SNU449 cells with FTCD overexpression. (B, D) Flow cytometric analysis of γH2AX-labeled BEL-7402 and SNU449 cells with FTCD overexpression. All experiments were performed in triplicate and results are expressed as means ±SD. ** P<0.01, *** P<0.001
Because cell apoptosis might be induced by DNA damage [13], flow cytometry analysis was performed on HCC cells with γ-H2AX-staining. The results showed that FTCD-overexpressing HCC cells had more γ-H2AX-positive cells than control cells (Figure 4B, 4D). Taken together, these data clearly show that FTCD inhibits cell proliferation by eliciting cell apoptosis and DNA damage.

**Overexpression of FTCD reduces PI3K/Akt pathway signaling**

The signaling pathway by which FTCD may promote cell proliferation has not been shown. Previous studies have shown that the PI3K/Akt pathway can maintain the function of Golgi apparatus [14]; therefore, we assessed whether there was a link between FTCD and the PI3K/Akt pathway. We found that FTCD overexpression resulted in an increase in expression of PTEN protein, but a marked loss of PI3K, total Akt, and phosphorylated Akt protein in BEL-7402 and SNU499 cells (Figure 5A, 5B). These data suggest that the anti-tumorigenic effects of FTCD in HCC occur via the PI3K-Akt pathway.

**Discussion**

Hepatocellular carcinoma (HCC) is a common malignant tumor worldwide [1,2]. Due to lack of typical symptoms, people with HCC are rarely diagnosed at the early stage, and most of them lose the opportunity for surgery [15]. Therefore, early diagnosis would significantly prolong the survival time and improve the quality of life of patients with HCC, and many researches have sought new molecular biological markers and therapeutic methods for HCC. In recent years, with the development of high-throughput sequencing technology, the technology of proteome analysis has become widely used in scientific research. Previous studies found that the expression level of FTCD was downregulated in HCC via proteome analysis [16,17]. In addition, Yu et al. found that FTCD was a downstream target of HIF-1α and the crosstalk between FTCD and HIF signaling promotes the progression of HCC [18]. FTCD had been shown to have an important role in the occurrence and development of HCC.

However, the exact mechanism by which FTCD expression is decreased in HCC remains unclear. Therefore, in this study, we conceived and designed in vivo and in vitro experiments to investigate the mechanism of action of FTCD in HCC. After analyzing the relationship between the FTCD expression and the clinicopathologic characteristics of HCC, we discovered that the expression levels of FTCD were negatively correlated with AFP levels, tumor size, vascular invasion, and pTNM stage, and higher expression of FTCD is associated with higher differentiation of HCC. Consistent with previous results, the IHC results indicated that FTCD expression was higher in the non-tumor tissues than in HCC tissues. This means that HCC patients...
with overexpression of FTCD have better prognosis and longer survival time. Consequently, FTCD could be used as a biological marker for HCC prognosis, which was in line with previous reports [10,19].

DNA methylation is one of the common modification methods that occur during genetic replication and transcription, contributing to gene expression, cell proliferation, and cell division, as well as the development of some gene-related diseases and cancers [20,21]. Fei et al. revealed that the methylation of p53 induced by SETDB1 promotes HCC cancer cell growth [22]. There is substantial evidence that DNA methylation plays an important role in the progression of HCC [23,24]; therefore, we further explored the relationship between the expression level of FTCD and DNA methylation. After researching and analyzing the TCGA-LIHC data set, we discovered higher methylation levels in the promoter region of FTCD for HCC tissues than in the non-tumor tissues. Then, a demethylation drug (5-Aza) [25] was used to knock-down the methylation levels in the BEL-7402 and SNU449 cells. Consistent with the TCGA-LIHC data set, the methylation levels were negatively associated with the expression level of FTCD. Furthermore, the results of CCK-8 and flow cytometry showed that FTCD overexpression could significantly inhibit cell proliferation and induce cell apoptosis. These results show that the low methylation levels in the promoter region of FTCD directly lead to FTCD overexpression, which can remarkably inhibit tumor growth.

Accordingly, overexpressed FTCD could be a potential therapy method for HCC treatment, but its specific anti-tumor mechanisms are not clear. Previous studies have shown that FTCD and the PI3K/Akt signaling pathway are closely related to the Golgi apparatus function [8,14], so we speculated that the anti-tumor mechanisms of FTCD occur via suppressing the PI3K/Akt signaling pathway. PI3K, an intracellular phosphatidylinositol kinase, is involved in the development of many malignant tumors, including nasopharyngeal cancer [26], breast cancer [27], and liver cancer [28,29]. There is increasing evidence that PI3K downregulates the expression of cell apoptosis regulatory proteins via the phosphorylation of Akt, which functions as a vital regulator of cell proliferation [30,31]. In addition, Jin et al. indicated that the PI3K/Akt/GSK3 pathway could inhibit cell apoptosis via enhancing Chk1-dependent G2/M checkpoint activation by etoposide [32]. Consequently, the suppression of PI3K/Akt signaling pathway can arrest more cells in the G2/M phase related to DNA damage [13], then lead to cell apoptosis. In this study, Western blot analysis was applied to investigate the expression level of PI3K/Akt signaling pathway-related proteins. Interestingly, we identified that both the expression level of PI3K and phosphorylated Akt protein were downregulated in HCC cells overexpressing FTCD. Moreover, the results of flow cytometric analysis showed that FTCD overexpression could induce more apoptotic cells and more γ-H2AX-positive cells, and both of these were associated with DNA damage. In fact, DNA damage is one of the most common factors leading to cell growth disorders [33,34]. Overexpression of FTCD in HCC cell lines can further suppress the PI3K/Akt pathway, which can contribute to DNA damage and cell apoptosis.

Conclusions

Our study clarifies the role of FTCD in the procession of HCC and its possible mechanisms, showing that DNA methylation can cause FTCD downregulation, then suppress the PI3K/Akt signaling pathway, followed by inhibiting tumor growth. Therefore, FTCD could be a promising biological marker and potential target to treat HCC.

Conflict of interests

None.

References:

1. Siegel RL, Miller KD, Jemal A: Cancer Statistics, 2017. Cancer J Clinm 2017; 67: 7–30
2. Maluccio M, Covey A: Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. Cancer J Clin, 2012; 62: 394–99
3. Okuda K: Hepatocellular carcinoma. J Hepatol, 2000; 32: 225–37
4. Simard EP, Ward EM, Siegel R, Jemal A: Cancers with increasing incidence trends in the United States: 1999 through 2008. Cancer J Clin, 2012; 62: 118–28
5. Moeini A, Cornella H, Villanueva A: Emerging signaling pathways in hepatocellular carcinoma. Liver Cancer, 2012; 1: 83–93
6. Bashour AM, Bloom GS: 58K, a microtubule-binding Golgi protein, is a formiminotransferase cyclodeaminase. J Biol Chem, 1998; 273: 19612–17
7. Kohls D, Sulea T, Purisima EO et al: The crystal structure of the formiminotransferase domain of formiminotransferase-cyclodeaminase: Implications for substrate channeling in a bifunctional enzyme. Structure, 2000; 8: 35–46
8. Hagiwara H, Tajiya Y, Matsuzaki T et al: Localization of Golgi 58K protein (formiminotransferase cyclodeaminase) to the centrosome. Histochem Cell Biol, 2006; 126: 251–59
9. Kanarek N, Keys HR, Cantor JR et al: Histidine catabolism is a major determinant of methotrexate sensitivity. Nature, 2018; 559: 632–36
10. Seimiya M, Tomonaga T, Matsuhashita K et al: Identification of novel immuno-histochemical tumor markers for primary hepatocellular carcinoma; Clathrin heavy chain and formiminotransferase cyclodeaminase. Hepatology, 2008; 48: 519–30
11. Ou H, Liu X, Xiang L et al: NVM-1 predicts prognosis and contributes to growth and metastasis in hepatocellular carcinoma. Am J Cancer Res, 2017; 7: 554–64
12. Ye G, Huang K, Yu J et al: MicroRNA-647 targets SRF-MYH9 axis to suppress invasion and metastasis of gastric cancer. Theranostics, 2017; 7: 3338–53
13. Yuan L, Yu WM, Qu CK: DNA damage-induced G2/M checkpoint in SV40 large T antigen-immortalized embryonic fibroblast cells requires SHP-2 tyrosine phosphatase. J Biol Chem, 2003; 278: 42812–20
14. Giussani P, Brioschi L, Bassi R et al: Phosphatidylinositol 3-kinase/AKT pathway regulates the endoplasmic reticulum to Golgi traffic of ceramide in glioma cells: A link between lipid signaling pathways involved in the control of cell survival. J Biol Chem, 2009; 284: 5088–96
15. Kobayashi T, Teruya M: Preoperative transarterial chemoembolization for resectable large hepatocellular carcinoma. Ann Surg, 2010; 251: 386; author reply 386–87

16. Sun W, Xing B, Sun Y et al: Proteome analysis of hepatocellular carcinoma by two-dimensional difference gel electrophoresis: Novel protein markers in hepatocellular carcinoma tissues. Mol Cell Proteomics, 2007; 6: 1798–808

17. Bruderer R, Bernhardt OM, Gandhi T et al: Extending the limits of quantitative proteome profiling with data-independent acquisition and application to acetaminophen-treated three-dimensional liver microtissues. Mol Cell Proteomics, 2015; 14: 1400–10

18. Yu Z, Ge Y, Xie L et al: Using a yeast two-hybrid system to identify FTCD as a new regulator for HIF-1alpha in HepG2 cells. Cell Signal, 2014; 26: 1560–66

19. Liu Z, Ma Y, Yang J, Qin H: Upregulated and downregulated proteins in hepatocellular carcinoma: A systematic review of proteomic profiling studies. OMICS, 2011; 15: 61–71

20. Goldberg AD, Allis CD, Bernstein E: Epigenetics: A landscape takes shape. Cell, 2007; 128: 635–38

21. Li E, Bestor TH, Jaenisch R: Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell, 1992; 69: 915–26

22. Fei Q, Shang K, Zhang J et al: Histone methyltransferase SETDB1 regulates liver cancer cell growth through methylation of p53. Nat Commun, 2015; 6: 8651

23. Kisiel JB, Dukek BA, Kanipakam R et al: Hepatocellular carcinoma detection by plasma methylated DNA: Discovery, Phase I pilot, and Phase II clinical validation. Hepatology, 2019; 69(3): 1180–92

24. Arechederra M, Daian F, Yim A et al: Hypermethylation of gene body CpG islands predicts high dosage of functional oncogenes in liver cancer. Nat Commun, 2018; 9: 3164

25. Yamashita AS, da Costa Rosa M, Borodovsky A et al: Demethylation and epigenetic modification with 5-Azacytidine reduces IDH1 mutant glioma growth in combination with Temozolomide. Neuro Oncol. 2018 [Epub ahead of print]

26. Zhao M, Luo R, Liu Y et al: miR-318B regulates nasopharyngeal carcinoma proliferation and chemosensitivity through a FOXO1-modulated positive feedback loop with mTOR-p-PI3K/akt-c-JUN. Nat Commun, 2016; 7: 11309

27. Delaloge S, DeForceville L: Targeting PI3K/akt pathway in triple-negative breast cancer. Lancet Oncol, 2017; 18: 1293–94

28. Zhang Y, Cong L, He J et al: Photothermal treatment with EGFrmAb-AuNPs induces apoptosis in hypopharyngeal carcinoma cells via PI3K/akt/mTOR and DNA damage response pathways. Acta Biochim Biophys Sin (Shanghai), 2018; 50: 567–78

29. Pellegrino R, Calvisi DF, Neumann O et al: EEF1A2 inactivates p53 by way of PI3K/akt/mTOR-dependent stabilization of MDM4 in hepatocellular carcinoma. Hepatology, 2014; 59: 1886–99

30. Ho L, Tan SY, Wee S et al: ELABELA is an endogenous growth factor that sustains hESC self-renewal via the PI3K/akt pathway. Cell Stem Cell, 2015; 17: 435–47

31. Teschendorff AE, Li L, Yang Z: Denoising perturbation signatures reveal an actionable AKT-signaling gene module underlying a poor clinical outcome in endocrine-treated ER+ breast cancer. Genome Biol, 2015; 16: 61

32. Jin ZH, Kurosu T, Yamaguchi M et al: Hematopoietic cytokines enhance Chk1-dependent G2/M checkpoint activation by etoposide through the AKT/GSK3 pathway to inhibit apoptosis. Oncogene, 2005; 24: 1973–81

33. Borges HI, Linden R, Wang JY: DNA damage-induced cell death: Lessons from the central nervous system. Cell Res, 2008; 18: 17–26

34. Zheng P, Chen Q, Tian X et al: DNA damage triggers tubular endoplasmic reticulum extension to promote apoptosis by facilitating ER-mitochondria signaling. Cell Res, 2018; 28: 833–54